ACA
CLDX icon

Atlas Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Atlas Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,700
Closed -$75.9K – 909
2022
Q3 		$75.9K Buy
+2,700
New +$82.8K 0.01% 483
2022
Q2 		– Sell
-2,700
Closed -$92K – 981
2022
Q1 		$92K Hold
2,700
– – 0.01% 480
2021
Q4 		$104K Hold
2,700
– – 0.02% 448
2021
Q3 		$146K Hold
2,700
– – 0.02% 394
2021
Q2 		$90.3K Sell
2,700
-300
-10% -$8.23K 0.02% 460
2021
Q1 		$61.8K Hold
3,000
– – 0.01% 476
2020
Q4 		$52.6K Buy
+3,000
New +$54K 0.01% 462

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Atlas Capital Advisors's CLDX Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2022, closing a stake of 2,700 shares — an estimated $75.9K sold.

Atlas Capital Advisors first reported a position in CLDX in Q4 2020 and held it in 7 quarters. The position peaked at $146K in Q3 2021. 167 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • Atlas Capital Advisors reported no remaining Celldex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 2,700 Celldex Therapeutics shares in Q4 2022, an estimated $75.9K.
  • Atlas Capital Advisors first reported a position in Celldex Therapeutics in Q4 2020 and held it in 7 quarters.
  • Atlas Capital Advisors's Celldex Therapeutics position peaked at $146K in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.